March 2010 Volume 28 Number 3, pp 181 - 292
Visit Nature Biotechnology online to browse the journal.
Now available at http://links.ealert.nature.com/ctt?kn=129&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access to Nature Biotechnology online. To purchase a subscription, please visit:
http://links.ealert.nature.com/ctt?kn=23&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=106&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Bioentrepreneur: an online resource for budding business in the life sciences.
http://links.ealert.nature.com/ctt?kn=181&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Attention: Chemists and Biologists Can you increase the stability of a nucleic acid? Your solution to increase the stability of small molecule RNA could win $20,000.
Click here to find out how. http://links.ealert.nature.com/ctt?kn=207&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
Dharmacon Duet siRNA Libraries are paired libraries of siGENOME and ON-TARGETplus SMARTpool siRNA reagents for higher confidence,
cost-effective siRNA screening.
> Raise confidence in primary screen results with two highly functional SMARTpool siRNA reagents
> Including ON-TARGETplus SMARTpools allows stratification of the most valid hits all within your primary screen
=====================================================================
=========================== ADVERTISEMENT ===========================
Now is the time - Help bring new multiple sclerosis treatments to market.
$3 million in funding available now for innovative research and commercial development proposals.
Who can apply?
> Seed and early stage companies
> Academic investigators
Click here to submit your proposal: http://links.ealert.nature.com/ctt?kn=42&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Fast ForwardSM - Driving promising research discoveries into development - faster.
=====================================================================
=========================== ADVERTISEMENT ===========================
BIOPARTNERING
Visit our Biopartnering site to view Company Profiles and Partnership Opportunities:
=====================================================================
=========================== ADVERTISEMENT ===========================
Natureevents Directory 2010
http://links.ealert.nature.com/ctt?kn=148&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
The FREE digital edition of the Natureevents Directory 2010 is now available!
Visit www.natureevents.com to download the complete resource forglobal scientific events and start planning your conference attendancefor the year ahead.
To advertise events please contact natureevents@nature.com
=====================================================================
----------------------
EDITORIALS
----------------------
America's got talent - can it keep it? p181
doi:10.1038/nbt0310-181
To remain competitive in biotech, policymakers should pay more attention to retaining skilled foreign workers than to fixating on illegal immigration.
http://links.ealert.nature.com/ctt?kn=104&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
H1N1dsight is a wonderful thing p182
doi:10.1038/nbt0310-182
Criticisms of the response of governments and of the pharmaceutical industry to the threat of the H1N1 epidemic are wide of the mark.
http://links.ealert.nature.com/ctt?kn=100&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
----------------------
NEWS
----------------------
Ark's gene therapy stumbles at the finish line pp183 - 184
Peter Mitchell
doi:10.1038/nbt0310-183
http://links.ealert.nature.com/ctt?kn=99&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Monsanto's alfalfa reaches Supreme Court p184
Boonsri Dickinson
doi:10.1038/nbt0310-184
http://links.ealert.nature.com/ctt?kn=101&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
GSK/Sirtris compounds dogged by assay artifacts pp185 - 186
Charlie Schmidt
doi:10.1038/nbt0310-185
http://links.ealert.nature.com/ctt?kn=50&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
US biodefense contracts continue to lure biotechs pp187 - 188
Catherine Shaffer
doi:10.1038/nbt0310-187
http://links.ealert.nature.com/ctt?kn=48&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Ride 'n Drive on government waste p188
doi:10.1038/nbt0310-188
http://links.ealert.nature.com/ctt?kn=46&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Melanoma vaccine for dogs p189
Suzanne Elvidge
doi:10.1038/nbt0310-189a
http://links.ealert.nature.com/ctt?kn=44&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Biotechs go virtual p189
Susan Aldridge
doi:10.1038/nbt0310-189b
http://links.ealert.nature.com/ctt?kn=57&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Chinese institute makes bold sequencing play pp189 - 191
John Fox and Jim Kling
doi:10.1038/nbt0310-189c
http://links.ealert.nature.com/ctt?kn=56&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
RNAi delivery shop p191
Nazlie Latefi
doi:10.1038/nbt0310-191a
http://links.ealert.nature.com/ctt?kn=52&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Brazil boosts bioscience p191
Ricardo Bonalume Neto
doi:10.1038/nbt0310-191b
http://links.ealert.nature.com/ctt?kn=51&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Patent income tax slashed p192
Asher Mullard
doi:10.1038/nbt0310-192a
http://links.ealert.nature.com/ctt?kn=60&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Abbott hit with record fine p192
Michael Francisco
doi:10.1038/nbt0310-192b
http://links.ealert.nature.com/ctt?kn=59&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Resuscitated deCODE refocuses on diagnostics p192
Mark Ratner
doi:10.1038/nbt0310-192c
http://links.ealert.nature.com/ctt?kn=11&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
NEWS FEATURES
One year in - Obama's biotech scorecard pp193 - 196
Jeffrey L Fox
doi:10.1038/nbt0310-193
As healthcare reform falters, the biotech industry awaits the fate of biosimilars and tax credits. Jeff Fox reports.
http://links.ealert.nature.com/ctt?kn=10&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
The lengthening handshake pp197 - 199
Randy Osborne
doi:10.1038/nbt0310-197
Although mergers and acquisitions (M&As) failed to hit the heights some analysts had predicted in 2009, a new type of tiered transaction rose to prominence[mdash]the structured deal. Randy Osborne reports.
http://links.ealert.nature.com/ctt?kn=9&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
----------------------
BIOENTREPRENEUR
----------------------
BUILDING A BUSINESS
Seeking the biotech eBay
Nuala Moran
doi:10.1038/bioe.2010.1
Internet exchanges suggest an easy route to sourcing and licensing technology, but can biotech intellectual property be packaged up and sold in this way?
http://links.ealert.nature.com/ctt?kn=8&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
----------------------
OPINION AND COMMENT
----------------------
CORRESPONDENCE
Oversulfated chondroitin sulfate is not the sole contaminant in heparin pp203 - 207
Jing Pan et al.
doi:10.1038/nbt0310-203
http://links.ealert.nature.com/ctt?kn=4&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Reply to Oversulfated chondroitin sulfate is not the sole contaminant in heparin pp207 - 211
doi:10.1038/nbt0310-207
http://links.ealert.nature.com/ctt?kn=3&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Why FDA recruitment of 'critics' is a problem p212
Henry I Miller
doi:10.1038/nbt0310-212a
http://links.ealert.nature.com/ctt?kn=2&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Genetic exceptionalism pp212 - 213
William Bains
doi:10.1038/nbt0310-212b
http://links.ealert.nature.com/ctt?kn=1&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
----------------------
FEATURES
----------------------
Lost in migration pp214 - 229
George S Mack and Andrew Marshall
doi:10.1038/nbt0310-214
Combinations of cytostatic treatments and chemotherapies currently in clinical practice offer limited hope for patients whose cancers have spread. But increasing understanding of the processes underlying metastasis may one day provide other therapeutic options.
http://links.ealert.nature.com/ctt?kn=7&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
PATENTS
Patenting biotech beyond the central dogma pp230 - 233
George Wu
doi:10.1038/nbt0310-230
Biotech inventors and patent practitioners alike need to be aware of new interpretations of what is considered patentable, and draft claims that extend beyond biological principles.
http://links.ealert.nature.com/ctt?kn=6&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Recent patent applications in DNA diagnostics p234
doi:10.1038/nbt0310-234
http://links.ealert.nature.com/ctt?kn=24&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Genetic therapy for spinal muscular atrophy pp235 - 237
Alex MacKenzie
doi:10.1038/nbt0310-235
A severe inherited neuromuscular disease is corrected in mice by intravenous gene delivery.
http://links.ealert.nature.com/ctt?kn=26&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Targeting leukemia stem cells pp237 - 238
Hanna K A Mikkola, Caius G Radu and Owen N Witte
doi:10.1038/nbt0310-237
Acute myeloid leukemia stem cells can be made susceptible to chemotherapy by inducing them to divide.
http://links.ealert.nature.com/ctt?kn=25&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Cellular targets for influenza drugs pp239 - 240
Ji-Young Min and Kanta Subbarao
doi:10.1038/nbt0310-239
High-throughput RNAi screens in human cells suggest new approaches to curb influenza virus infection.
http://links.ealert.nature.com/ctt?kn=28&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Navigating genomic maps of cancer cells pp241 - 242
Marcel P van der Brug and Claes Wahlestedt
doi:10.1038/nbt0310-241
What can we learn from the first genome sequences obtained from cancerous cells?
http://links.ealert.nature.com/ctt?kn=27&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Grass genomics on the wild side p242
Craig Mak
doi:10.1038/nbt0310-242
http://links.ealert.nature.com/ctt?kn=18&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Research highlights p243
Markus Elsner, Laura DeFrancesco and Craig Mak
doi:10.1038/nbt0310-243
http://links.ealert.nature.com/ctt?kn=17&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
----------------------
COMPUTATIONAL BIOLOGY
----------------------
PRIMER
What is flux balance analysis? pp245 - 248
Jeffrey D Orth, Ines Thiele and Bernhard O Palsson
doi:10.1038/nbt.1614
Flux balance analysis is a mathematical approach for analyzing the flow of metabolites through a metabolic network. This primer covers the theoretical basis of the approach, several practical examples and a software toolbox for performing the calculations.
http://links.ealert.nature.com/ctt?kn=21&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
----------------------
RESEARCH
----------------------
ARTICLES
Nutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis pp249 - 255
Vishal M Gohil et al.
doi:10.1038/nbt.1606
Many diseases are characterized by shifts in cellular energy metabolism. Gohil et al. use a quantitative, nutrient-sensitized screen to identify drugs that affect the relative rates of glycolysis and mitochondrial respiration, and demonstrate the protective capacity of an approved antiemetic in models of cardiac and cerebral ischemia.
Abstract: http://links.ealert.nature.com/ctt?kn=19&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=22&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein pp256 - 263
Peter O Bauer et al.
doi:10.1038/nbt.1608
Decreasing levels of mutant, but not normal, huntingtin (HTT) protein remains a major obstacle to treating Huntington's disease (HD). Bauer et al. show that a fusion of polyglutamine-and HSC70-binding motifs specifically targets mutant HTT for degradation by chaperone-mediated autophagy and ameliorates the phenotype of a mouse model of HD.
Abstract: http://links.ealert.nature.com/ctt?kn=71&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=72&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Directed evolution of a magnetic resonance imaging contrast agent for noninvasive imaging of dopamine pp264 - 270
Mikhail G Shapiro et al.
doi:10.1038/nbt.1609
Magnetic resonance imaging of hemoglobin in the brain can detect blood flow associated with neural activity, but direct imaging of neurotransmitters would provide a more sensitive measure of neural signal processing. Shapiro et al. use directed evolution to generate a protein probe that enables magnetic resonance imaging of the neurotransmitter dopamine.
Abstract: http://links.ealert.nature.com/ctt?kn=69&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=70&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
LETTERS
Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN pp271 - 274
Kevin D Foust et al.
doi:10.1038/nbt.1610
Spinal muscular atrophy is an autosomal recessive disease of motor neurons caused by lack of the SMN gene. Foust et al. achieve long-term correction of the disease phenotype in a mouse model by intravenous delivery of SMN using the viral vector scAAV9.
Abstract: http://links.ealert.nature.com/ctt?kn=67&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=68&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML pp275 - 280
Yoriko Saito et al.
doi:10.1038/nbt.1607
In acute myeloid leukemia, a sub-population of quiescent cancer cells, called leukemia stem cells, is thought to be responsible for chemotherapy resistance and eventual recurrence of the disease. Saito et al. show that treatment with granulocyte colony-stimulating factor can overcome resistance to standard therapy by inducing cell cycle entry of the leukemia stem cells.
Abstract: http://links.ealert.nature.com/ctt?kn=78&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=79&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products pp281 - 288
Oded Kleifeld et al.
doi:10.1038/nbt.1611
Many proteases are important drug targets, but identification of their substrates remains challenging. By using polymers to selectively isolate N-terminal peptides generated by proteolysis of complex samples, Kleifeld et al. identify substrates of clinically relevant proteases with broad specificity.
Abstract: http://links.ealert.nature.com/ctt?kn=75&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=77&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
----------------------
CAREERS AND RECRUITMENT
----------------------
The importance of foreign-born talent for US innovation pp289 - 291
Yeonji No and John P Walsh
doi:10.1038/nbt0310-289
A survey suggests that foreign-born scientists and engineers play a major role in scientific and innovation output in the United States.
http://links.ealert.nature.com/ctt?kn=93&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
PEOPLE
People p292
doi:10.1038/nbt0310-292
http://links.ealert.nature.com/ctt?kn=94&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
FREE ARTICLES FROM SciBX
Neurology: Methylene-specific oxidation in natural products
Full text: http://links.ealert.nature.com/ctt?kn=159&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
PDF: http://links.ealert.nature.com/ctt?kn=155&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Neurology: Targeting serotonin autoreceptors to boost antidepressant efficacy
Full text: http://links.ealert.nature.com/ctt?kn=154&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
PDF: http://links.ealert.nature.com/ctt?kn=153&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
Cancer: Targeting CXCR1 in breast cancer growth and metastasis
Full text:http://links.ealert.nature.com/ctt?kn=33&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
PDF: http://links.ealert.nature.com/ctt?kn=32&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
ACCESS MORE THAN 40 FREE ARTICLES from the SciBX Cover Story Archive
http://links.ealert.nature.com/ctt?kn=5&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to
receive it. You can change or discontinue your e-mail alerts at any time,
by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=64&m=34685620&r=MTc3MTg2NzE2NgS2&b=2&j=Njg2NDE4ODgS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2010 Nature Publishing Group
=====================================================================
